Raloxifenum [Latin] en es it fr

Raloxifenum [Latin] Brand names, Raloxifenum [Latin] Analogs

Raloxifenum [Latin] Brand Names Mixture

  • No information avaliable

Raloxifenum [Latin] Chemical_Formula


Raloxifenum [Latin] RX_link


Raloxifenum [Latin] fda sheet

Raloxifenum_[Latin] FDA

Raloxifenum [Latin] msds (material safety sheet)

Raloxifenum_[Latin] MSDS

Raloxifenum [Latin] Synthesis Reference

C. D. Jones et al., J. Med. Cem. 27, 1057(1984)

Raloxifenum [Latin] Molecular Weight

473.584 g/mol

Raloxifenum [Latin] Melting Point


Raloxifenum [Latin] H2O Solubility


Raloxifenum [Latin] State


Raloxifenum [Latin] LogP


Raloxifenum [Latin] Dosage Forms


Raloxifenum [Latin] Indication

For the prevention of osteoporosis in post-menopausal women

Raloxifenum [Latin] Pharmacology

Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer.

Raloxifenum [Latin] Absorption

Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%

Raloxifenum [Latin] side effects and Toxicity

No information avaliable

Raloxifenum [Latin] Patient Information


For safe and effective use of EVISTA, the physician should inform patients about the following:

Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.

Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.

Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.

Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.

Raloxifenum [Latin] Organisms Affected

Humans and other mammals